Galectin Therapeutics Inc. (FRA:PHPN)

Market Cap	287.29M +6.7%
Revenue (ttm)	n/a
Net Income	-24.53M
EPS	-0.38
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	690
Open	2.980
Previous Close	2.940
Day's Range	2.680 - 2.980
52-Week Range	1.610 - 5.800
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 9
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PHPN

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error